Klaus Schwamborn is currently leading as Vice President the Vaccine Research at Valneva SE and serves as a director of BlinK Biomedical SAS. He is dedicated to innovative approaches and technologies to generate novel vaccine candidates. Before joining Valneva he held positions of increasing responsibility at Pepscan Therapeutics and Celgene. Klaus has broad international experience in drug discovery and research in infectious diseases and oncology including the areas of therapeutics antibodies and peptide based biologics. Klaus received his PhD from the University of Göttingen and completed postdoctoral studies at the Institute Pasteur Paris.